Please select the option that best describes you:
How would you apply the results of CheckMate 204 in an asymptomatic patient with 10-20 metastatic brain lesions on dual immunotherapy for melanoma?
The majority of patients in CheckMate 204 had 1-2 metastatic lesions.
Answer from: Radiation Oncologist at Academic Institution
The results of CheckMate 204 showed that systemic therapy with both nivolumab and ipilimumab has clinically meaningful efficacy in patients with asymptomatic, untreated melanoma metastases to the brain. In this phase 2 study, however, only 22% of the patients had 3 or more lesions. Nevertheless, int...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
In asymptomatic patients receiving effective systemic immunotherapy, local therapies (surgery or radiation) may be deferred unless there is evidence of progression or new symptoms in patients with multiple brain metastases. (Kattenhøj et al., PMID 39061198; Vogelbaum et al., PMID 34932393)Evi...
Answer from: Medical Oncologist at Academic Institution
I start immunotherapy and try to get Dex weaned quickly. Typically, we tend to combine immunotherapy with concurrent GKRS and have had good outcomes. We also check BRAF status, so we have TKIs as backup since BRAF inhibitors cross the BBB in the event of failure of IO and GKRS.